Carterra is a biotechnology company that develops and commercializes high-throughput surface plasmon resonance (HT-SPR) solutions for drug discovery and development. The company's proprietary LSA (laser scanning cytometry) technology enables the screening of large numbers of antibodies and other proteins in a single experiment, providing researchers with a more efficient and cost-effective way to identify potential drug candidates. Carterra's technology has been adopted by leading pharmaceutical and biotechnology companies, as well as academic research institutions around the world.